Calapai, F.; Ammendolia, I.; Cardia, L.; Currò, M.; Calapai, G.; Esposito, E.; Mannucci, C.
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database. Pharmaceutics 2023, 15, 1933.
https://doi.org/10.3390/pharmaceutics15071933
AMA Style
Calapai F, Ammendolia I, Cardia L, Currò M, Calapai G, Esposito E, Mannucci C.
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database. Pharmaceutics. 2023; 15(7):1933.
https://doi.org/10.3390/pharmaceutics15071933
Chicago/Turabian Style
Calapai, Fabrizio, Ilaria Ammendolia, Luigi Cardia, Mariaconcetta Currò, Gioacchino Calapai, Emanuela Esposito, and Carmen Mannucci.
2023. "Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database" Pharmaceutics 15, no. 7: 1933.
https://doi.org/10.3390/pharmaceutics15071933
APA Style
Calapai, F., Ammendolia, I., Cardia, L., Currò, M., Calapai, G., Esposito, E., & Mannucci, C.
(2023). Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database. Pharmaceutics, 15(7), 1933.
https://doi.org/10.3390/pharmaceutics15071933